Latest Insider Transactions at Ligand Pharmaceuticals Inc (LGND)
This section provides a real-time view of insider transactions for Ligand Pharmaceuticals Inc (LGND). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of LIGAND PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of LIGAND PHARMACEUTICALS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 10
2025
|
John W Kozarich Director |
SELL
Open market or private sale
|
Direct |
934
-1.97%
|
$116,750
$125.0 P/Share
|
|
Jun 30
2025
|
Todd C Davis Chief Executive Officer |
BUY
Other acquisition or disposition
|
Direct |
233
+0.14%
|
$21,203
$91.08 P/Share
|
|
Jun 30
2025
|
Octavio Espinoza Chief Financial Officer |
BUY
Other acquisition or disposition
|
Direct |
224
+0.74%
|
$20,384
$91.08 P/Share
|
|
Jun 30
2025
|
Andrew Reardon CLO & Secretary |
BUY
Other acquisition or disposition
|
Direct |
233
+0.72%
|
$21,203
$91.08 P/Share
|
|
Jun 23
2025
|
Andrew Reardon CLO & Secretary |
SELL
Open market or private sale
|
Direct |
500
-1.54%
|
$57,000
$114.08 P/Share
|
|
Jun 10
2025
|
Andrew Reardon CLO & Secretary |
SELL
Open market or private sale
|
Direct |
500
-1.52%
|
$57,000
$114.54 P/Share
|
|
Jun 06
2025
|
Jason Aryeh Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,209
+1.5%
|
-
|
|
Jun 06
2025
|
Nancy Ryan Gray Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,209
+13.0%
|
-
|
|
Jun 06
2025
|
Jason Haas Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,209
+15.47%
|
-
|
|
Jun 06
2025
|
John W Kozarich Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,209
+2.49%
|
-
|
|
Jun 06
2025
|
Stephen L Sabba Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,209
+3.45%
|
-
|
|
Jun 06
2025
|
Martine Zimmermann Director |
SELL
Payment of exercise price or tax liability
|
Direct |
188
-3.96%
|
$19,740
$105.99 P/Share
|
|
Jun 06
2025
|
Martine Zimmermann Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,209
+20.3%
|
-
|
|
Jun 06
2025
|
John L Lamattina Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,209
+3.79%
|
-
|
|
May 15
2025
|
Andrew Reardon CLO & Secretary |
SELL
Open market or private sale
|
Direct |
1,000
-2.95%
|
$104,000
$104.0 P/Share
|
|
May 09
2025
|
Todd C Davis Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
9,510
+1.95%
|
$989,040
$104.92 P/Share
|
|
May 09
2025
|
Octavio Espinoza Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
1,500
+2.64%
|
$156,000
$104.15 P/Share
|
|
Apr 01
2025
|
Stephen L Sabba Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,406
+6.88%
|
$125,112
$52.3 P/Share
|
|
Mar 04
2025
|
Todd C Davis Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,382
+12.35%
|
-
|
|
Mar 04
2025
|
Octavio Espinoza Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,484
+22.11%
|
-
|
|
Mar 04
2025
|
Octavio Espinoza Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-20.94%
|
$575,000
$115.03 P/Share
|
|
Mar 04
2025
|
Andrew Reardon CLO & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
6,415
+15.57%
|
-
|
|
Feb 15
2025
|
Todd C Davis Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,486
-2.4%
|
$778,320
$120.0 P/Share
|
|
Feb 15
2025
|
Andrew Reardon CLO & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
1,990
-3.33%
|
$238,800
$120.0 P/Share
|
|
Feb 15
2025
|
Octavio Espinoza Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,027
-3.9%
|
$363,240
$120.0 P/Share
|
|
Feb 14
2025
|
Todd C Davis Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,966
-4.84%
|
$835,920
$120.0 P/Share
|
|
Feb 14
2025
|
Todd C Davis Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,784
+12.63%
|
-
|
|
Feb 14
2025
|
Andrew Reardon CLO & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
4,533
-7.45%
|
$543,960
$120.0 P/Share
|
|
Feb 14
2025
|
Andrew Reardon CLO & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
12,357
+16.75%
|
-
|
|
Feb 14
2025
|
Octavio Espinoza Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,560
-11.48%
|
$787,200
$120.0 P/Share
|
|
Feb 14
2025
|
Octavio Espinoza Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,819
+18.31%
|
-
|
|
Jan 17
2025
|
John W Kozarich Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,406
+4.95%
|
$125,112
$52.3 P/Share
|
|
Dec 23
2024
|
Octavio Espinoza Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,104
-9.25%
|
$244,064
$116.37 P/Share
|
|
Dec 05
2024
|
Octavio Espinoza Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,859
-7.55%
|
$228,657
$123.51 P/Share
|
|
Nov 27
2024
|
John L Lamattina Director |
SELL
Open market or private sale
|
Direct |
2,406
-7.54%
|
$295,938
$123.65 P/Share
|
|
Nov 27
2024
|
John L Lamattina Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,406
+7.01%
|
$125,112
$52.3 P/Share
|
|
Sep 23
2024
|
Andrew Reardon CLO & Secretary |
SELL
Open market or private sale
|
Direct |
2,000
-8.15%
|
$198,000
$99.6 P/Share
|
|
Sep 23
2024
|
Andrew Reardon CLO & Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+7.54%
|
$104,000
$52.27 P/Share
|
|
Sep 23
2024
|
Matthew E Korenberg President & COO |
SELL
Open market or private sale
|
Direct |
9,772
-5.57%
|
$986,972
$101.24 P/Share
|
|
Sep 23
2024
|
Matthew E Korenberg President & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,772
+7.09%
|
$498,372
$51.42 P/Share
|
|
Sep 20
2024
|
Matthew E Korenberg President & COO |
SELL
Open market or private sale
|
Direct |
6,275
-11.0%
|
$652,600
$104.1 P/Share
|
|
Sep 20
2024
|
Matthew E Korenberg President & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,982
+8.03%
|
$244,118
$49.99 P/Share
|
|
Sep 20
2024
|
Octavio Espinoza Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,275
-1.66%
|
$131,325
$103.93 P/Share
|
|
Sep 17
2024
|
Octavio Espinoza Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,486
+2.73%
|
$101,048
$68.97 P/Share
|
|
Sep 16
2024
|
Matthew E Korenberg President & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,214
-1.53%
|
$337,470
$105.0 P/Share
|
|
Sep 16
2024
|
Matthew E Korenberg President & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,774
+2.64%
|
$323,344
$56.29 P/Share
|
|
Aug 28
2024
|
Octavio Espinoza Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
753
+1.52%
|
$47,439
$63.63 P/Share
|
|
Aug 28
2024
|
Andrew Reardon CLO & Secretary |
SELL
Open market or private sale
|
Direct |
1,500
-6.24%
|
$159,000
$106.39 P/Share
|
|
Aug 28
2024
|
Andrew Reardon CLO & Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+5.87%
|
$78,000
$52.27 P/Share
|
|
Aug 26
2024
|
Matthew E Korenberg President & COO |
SELL
Open market or private sale
|
Direct |
11,389
-9.83%
|
$1,195,845
$105.67 P/Share
|